Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avantium Pharma, a technology company specialized in the area of advanced high-throughput R&D, has been spun out from Avantium Holding in a management buy-out to create Crystallics, as part of its strategic plan to focus on cleantech and chemicals activities.
Subscribe to our email newsletter
The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract manufacturing organizations and agrochemical companies.
Crystallics is a science driven contract research organization specializing in pre-formulation and identification of the physical forms of drug substances, including polymorphs, salts, co-crystals and amorphous phases.
Screening, characterization and selection of solid forms, as well as crystallization process development and optimization will be the main focus.
CEO Gunnar Staaf said Crystallics’ core business focus will be in solid state research and pre-formulation, an area where they have built up considerable expertise over the last decade and their proprietary technology, experienced team, together with a strong customer focus, make Crystallics an ideal partner.
Chief scientific officer Marcel Hoffmann said they believe in a tailored, science based approach to meet the customer’s project objectives and budgets and, quality and speed will be at the heart of their research approach.